II. Indications
- Intolerance to ACE Inhibitor
- See ACE Inhibitor for indications
III. Contraindications
- See ACE Inhibitor for contraindications
-
Angioedema with ACE Inhibitor (relative contraindication)
- Bradykinin related reaction that recurs with ARBs in 2% of patients who had Angioedema on ACE Inhibitor
- Do not use ARB if ACE inhibitor Induced Angioedema was severe
- Precautions given to patient to stop ARB immediately and seak emergency care for signs of Angioedema recurrence
- Wait at least 4 weeks between stopping ACE Inhibitor and starting ARB
- (2013) J Allergy Clin Immunol 131:1491-3 [PubMed]
IV. Mechanism
V. Preparations: ARB alone
- Losartan (Cozaar)
- Start: 50 mg orally daily or 25 mg daily if volume depleted (MAX 100 mg/day)
- Consider twice daily divided dosing
- Irbesartan (Avapro)
- Start 150 mg orally daily (max 300 mg/day)
- Candesartan (Atacand)
- Start 8 mg orally daily (maximum 32 mg/day)
- Eprosartan (Teveten)
- Start 400 mg orally daily (maximum 800 mg/day)
- Telmisartan (Micardis)
- Start 40 mg orally daily (maximum 80 mg/day)
- Valsartan (Diovan)
- Start 80 mg orally daily (maximum 320 mg/day)
- Olmesartan (Benicar)
- Start 20 mg orally daily (maximum 40 mg/day)
- Azilsartan (Edarbi)
- Start 40 mg orally daily (maximum 80 mg/day)
VI. Preparations: Combination
-
Amlodipine (and ARB)
- Exforge (Amlodipine and Valsartan)
- Azor (Amlodipine and Olmesartan)
-
Hydrochlorothiazide (and ARB)
- Most ARB agents are available in combination with Hydrochlorothiazide (Hctz)
- Sacubitril and Valsartan (Entresto)
- Indicated in Systolic Dysfunction
- Sacubitril (neprilysin inhibitor) increases vasodilation and Sodium excretion
- Risk of Hypotension (Number needed to harm 21)
- Risk of Angioedema (Number needed to harm 200)
- See Systolic Dysfunction for dosing and references
VII. Protocol: Equivalent dosing (switching between agents)
- Losartan (Cozaar) 100 mg daily or divided twice daily
- Irbesartan (Avapro) 300 mg daily
- Candesartan (Atacand) 16 mg daily
- Eprosartan (Teveten) 800 mg daily
- Telmisartan (Micardis) 40 mg daily
- Valsartan (Diovan) 160 mg daily
- Olmesartan (Benicar) 20 mg daily
- Azilsartan (Edarbi) 40 mg daily
VIII. Efficacy
- Peak effect may require 4-6 weeks
- Proteinuria control is equivalent to ACE Inhibitors
- Evidence as of 2015 shows similar efficacy of ARBs as ACE Inhibitors in Myocardial Infarction prevention
- (2016) Presc Lett 23(3): 13
- Avoid in combination with ACE Inhibitors
- No advantage to combinations in Hypertension, vascular disease, Diabetes Mellitus, Coronary Artery Disease
- Moderate benefit of combination therapy in Congestive Heart Failure
- (2013) Prescr Lett 20(3): 13
- Reduce cardiovascular death, Cerebrovascular Accident and Myocardial Infarction risk
- Higher level cardiovascular protection than Atenolol
- However Atenolol is not the best Beta Blocker for cardiovascular disease prevention
- Dahlof (2002) Lancet 359:995-1003 [PubMed]
- ARBs do not effect Angiotensin II type 2 receptors
- Results in less effect on fibrosis and Blood Flow
- Unlike ACE Inhibitors, ARBs don't effect nitric oxide
- (2005) Prescriber's Letter 12:31-2
- Higher level cardiovascular protection than Atenolol
IX. Adverse Effects
- Valsartan (Diovan), Irbesartan (Avapro) and Losartan (Cozaar)
- N-Nitrosodimethylamine (NMDA) or N-nitrosodiethylamine (NDEA) product contamination (FDA recall 2018)
- https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm
- https://www.fda.gov/Safety/Recalls/ucm624593.htm
- https://www.fda.gov/Safety/Recalls/ucm625492.htm
- Product contamination may have been for as long as 4 years
- Cancer risk 1 in 8000 patients taking Valsartan for 8 years at 320 mg/day
- (2018) Presc Lett 25(9): 49
- N-Nitrosodimethylamine (NMDA) or N-nitrosodiethylamine (NDEA) product contamination (FDA recall 2018)
- Olmesartan (Benicar)
- Sprue-like Enteropathy
- Presents with progressive, severe Chronic Diarrhea, weight loss and sprue-like intestinal changes
- May be a delayed Hypersensitivity Reaction (typically months to years after starting Olmesartan)
- Rubio-Tapia (2012) Mayo Clin Proc 87(8):732-8 [PubMed]
- Sprue-like Enteropathy
Images: Related links to external sites (from Bing)
Related Studies
losartan (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
LOSARTAN POTASSIUM 100 MG TAB | Generic | $0.06 each |
LOSARTAN POTASSIUM 25 MG TAB | Generic | $0.04 each |
LOSARTAN POTASSIUM 50 MG TAB | Generic | $0.04 each |
LOSARTAN-HYDROCHLOROTHIAZIDE 100-12.5 MG TAB | Generic | $0.09 each |
LOSARTAN-HYDROCHLOROTHIAZIDE 100-25 MG TAB | Generic | $0.09 each |
LOSARTAN-HYDROCHLOROTHIAZIDE 50-12.5 MG TAB | Generic | $0.07 each |
cozaar (on 6/8/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
COZAAR 100 MG TABLET | Generic | $0.06 each |
COZAAR 50 MG TABLET | Generic | $0.04 each |
irbesartan (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
IRBESARTAN 150 MG TABLET | Generic | $0.16 each |
IRBESARTAN 300 MG TABLET | Generic | $0.25 each |
IRBESARTAN 75 MG TABLET | Generic | $0.17 each |
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB | Generic | $0.22 each |
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB | Generic | $0.31 each |
avapro (on 4/7/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
AVAPRO 150 MG TABLET | Generic | $0.16 each |
AVAPRO 300 MG TABLET | Generic | $0.25 each |
candesartan (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CANDESARTAN CILEXETIL 16 MG TB | Generic | $1.75 each |
CANDESARTAN CILEXETIL 32 MG TB | Generic | $2.66 each |
CANDESARTAN CILEXETIL 4 MG TAB | Generic | $2.15 each |
CANDESARTAN CILEXETIL 8 MG TAB | Generic | $1.89 each |
CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB | Generic | $3.14 each |
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB | Generic | $3.22 each |
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB | Generic | $3.90 each |
atacand (on 9/21/2016 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ATACAND 16 MG TABLET | Generic | $1.75 each |
ATACAND 32 MG TABLET | Generic | $2.66 each |
telmisartan (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TELMISARTAN 20 MG TABLET | Generic | $0.47 each |
TELMISARTAN 40 MG TABLET | Generic | $0.45 each |
TELMISARTAN 80 MG TABLET | Generic | $0.44 each |
TELMISARTAN-AMLODIPINE 80-5 MG | Generic | $3.79 each |
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB | Generic | $2.70 each |
TELMISARTAN-HYDROCHLOROTHIAZIDE 80-12.5 MG TB | Generic | $2.47 each |
TELMISARTAN-HYDROCHLOROTHIAZIDE 80-25 MG TAB | Generic | $2.30 each |
micardis (on 1/4/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
MICARDIS 20 MG TABLET | Generic | $0.47 each |
MICARDIS 40 MG TABLET | Generic | $0.45 each |
MICARDIS 80 MG TABLET | Generic | $0.44 each |
MICARDIS HCT 40-12.5 MG TABLET | Generic | $2.70 each |
MICARDIS HCT 80-12.5 MG TABLET | Generic | $2.47 each |
MICARDIS HCT 80-25 MG TABLET | Generic | $2.30 each |
valsartan (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
VALSARTAN 160 MG TABLET | Generic | $0.13 each |
VALSARTAN 320 MG TABLET | Generic | $0.21 each |
VALSARTAN 40 MG TABLET | Generic | $0.10 each |
VALSARTAN 80 MG TABLET | Generic | $0.11 each |
VALSARTAN-HYDROCHLOROTHIAZIDE 160-12.5 MG TAB | Generic | $0.18 each |
VALSARTAN-HYDROCHLOROTHIAZIDE 160-25 MG TAB | Generic | $0.25 each |
VALSARTAN-HYDROCHLOROTHIAZIDE 320-12.5 MG TAB | Generic | $0.27 each |
VALSARTAN-HYDROCHLOROTHIAZIDE 320-25 MG TAB | Generic | $0.28 each |
VALSARTAN-HYDROCHLOROTHIAZIDE 80-12.5 MG TAB | Generic | $0.17 each |
diovan (on 1/4/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
DIOVAN 160 MG TABLET | Generic | $0.13 each |
DIOVAN 320 MG TABLET | Generic | $0.21 each |
DIOVAN 40 MG TABLET | Generic | $0.10 each |
DIOVAN 80 MG TABLET | Generic | $0.11 each |
DIOVAN HCT 160-12.5 MG TAB | Generic | $0.18 each |
DIOVAN HCT 160-25 MG TABLET | Generic | $0.25 each |
DIOVAN HCT 320-12.5 MG TAB | Generic | $0.27 each |
DIOVAN HCT 320-25 MG TABLET | Generic | $0.28 each |
DIOVAN HCT 80-12.5 MG TABLET | Generic | $0.17 each |
olmesartan (on 6/14/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
OLMESARTAN MEDOXOMIL 20 MG TAB | Generic | $3.69 each |
OLMESARTAN MEDOXOMIL 40 MG TAB | Generic | $5.11 each |
OLMESARTAN MEDOXOMIL 5 MG TAB | Generic | $3.10 each |
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB | Generic | $3.75 each |
OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB | Generic | $5.16 each |
OLMESARTAN-HYDROCHLOROTHIAZIDE 40-25 MG TAB | Generic | $5.61 each |
benicar (on 12/30/2016 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
BENICAR 20 MG TABLET | Generic | $3.69 each |
BENICAR 40 MG TABLET | Generic | $5.11 each |
BENICAR 5 MG TABLET | Generic | $3.10 each |
BENICAR HCT 20-12.5 MG TABLET | Generic | $3.75 each |
BENICAR HCT 40-12.5 MG TABLET | Generic | $5.16 each |
BENICAR HCT 40-25 MG TABLET | Generic | $5.61 each |
entresto (on 2/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ENTRESTO 24 MG-26 MG TABLET | $6.48 each | |
ENTRESTO 49 MG-51 MG TABLET | $6.49 each | |
ENTRESTO 97 MG-103 MG TABLET | $6.51 each | |
exforge (on 2/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
EXFORGE 10-160 MG TABLET | Generic | $0.61 each |
EXFORGE 10-320 MG TABLET | Generic | $0.63 each |
EXFORGE 5-160 MG TABLET | Generic | $0.40 each |
EXFORGE 5-320 MG TABLET | Generic | $0.62 each |
EXFORGE HCT 10-160-12.5 MG TAB | Generic | $2.54 each |
EXFORGE HCT 10-160-25 MG TAB | Generic | $3.20 each |
EXFORGE HCT 10-320-25 MG TAB | Generic | $3.05 each |
EXFORGE HCT 5-160-12.5 MG TAB | Generic | $1.94 each |
EXFORGE HCT 5-160-25 MG TAB | Generic | $2.93 each |
azor (on 12/30/2016 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
AZOR 10-20 MG TABLET | Generic | $0.88 each |
AZOR 10-40 MG TABLET | Generic | $1.09 each |
AZOR 5-20 MG TABLET | Generic | $0.91 each |
AZOR 5-40 MG TABLET | Generic | $1.09 each |
Ontology: Losartan (C0126174)
Definition (CHV) | a drug used to treat hypertension |
Definition (CHV) | a drug used to treat hypertension |
Definition (NCI_NCI-GLOSS) | A drug used to treat high blood pressure. Losartan blocks the action of chemicals that make blood vessels constrict (get narrower). It is a type of angiotensin II receptor antagonist. |
Definition (NCI) | The potassium salt form of losartan, a non-peptide angiotensin II antagonist with antihypertensive activity. Losartan potassium selectively and competitively blocks the binding of angiotensin II to the angiotensin I (AT1) receptor. Angiotensin II, formed from angiotensin I by angiotensin-converting enzyme (ACE), stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Losartan potassium, by blocking the binding of angiotensin II to the AT 1 receptor, promotes vasodilatation and decreases the effects of aldosterone. |
Definition (MSH) | An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. |
Definition (CSP) | antihypertensive agent; nonpeptide angiotension 1 subtype; angiotension 2 receptor antagonist/inhibitor. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D019808 |
SnomedCT | 373567002, 96309000 |
LNC | LP171619-2 |
English | Losartan, lozartan, 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol, 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol, Losartan [Chemical/Ingredient], LOSARTAN, losartan, Losartan (product), Losartan (substance) |
Swedish | Losartan |
Czech | losartan |
Finnish | Losartaani |
Russian | LOZARTAN, ЛОЗАРТАН |
Japanese | ロサルタン, ロザルタン |
Croatian | LOSARTAN |
Spanish | losartano, Losartán, losartano (sustancia), losartán (producto), losartán (sustancia), losartán |
Polish | Losartan |
French | Losartan |
Portuguese | Losartano, Losartan |
German | Losartan |
Italian | Losartan |
Ontology: valsartan (C0216784)
Definition (NCI) | An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure. |
Definition (PDQ) | An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464172&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=464172&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47781" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081489 |
SnomedCT | 108581009, 386876001 |
LNC | LP171649-9 |
English | N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine, valsartan, L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, valsartan (medication), VALSARTAN, valsartan [Chemical/Ingredient], Valsartan, Valsartan (product), Valsartan (substance) |
Spanish | valsartano, valsartano (sustancia), valsartán (producto), valsartán (sustancia), valsartán |
Ontology: telmisartan (C0248719)
Definition (NCI) | A benzimidazole derivative and a non-peptide angiotensin II receptor antagonist with antihypertensive property. Telmisartan selectively antagonizes angiotensin II binding to the AT1 subtype receptor, located in vascular smooth muscle and adrenal gland. The antagonism results in vasodilation and inhibits the angiotensin II-mediated aldosterone production, which in turn leading to a decrease in sodium and water as well as an increase in potassium excretion leading to a subsequent reduction in blood pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C084178 |
SnomedCT | 318985000, 129487008, 387069000 |
LNC | LP171643-2 |
English | (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid, 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic Acid, (1,1'-Biphenyl)-2-carboxylic Acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-, telmisartan (medication), telmisartan, telmisartan [Chemical/Ingredient], TELMISARTAN, Telmisartan (product), Telmisartan (substance), Telmisartan |
Spanish | telmisartano (sustancia), telmisartano, telmisartán (producto), telmisartán (sustancia), telmisartán |
Ontology: eprosartan (C0287041)
Definition (NCI) | A competitive and reversible angiotensin II receptor antagonist with anti-hypertensive property. Eprosartan blocks the binding of angiotensin II to the angiotensin (AT)1 receptor in vascular smooth muscle, thereby blocking the principal pressor action of angiotensin II on the renin-angiotensin system resulting in vascular dilatation. In addition, this agent blocks angiotensin II -induced stimulation of aldosterone synthesis and secretion by the adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Furthermore, eprosartan inhibits sympathetic norepinephrine production, thereby further reducing blood pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C068373 |
SnomedCT | 318990002, 396044005 |
English | eprosartan, eprosartan [Chemical/Ingredient], EPROSARTAN, Eprosartan (product), Eprosartan (substance), Eprosartan, 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)- |
Spanish | eprosartán (producto), eprosartán (sustancia), eprosartán |
Ontology: irbesartan (C0288171)
Definition (NCI) | A nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. (NCI05) |
Definition (CSP) | antihypertensive; nonpeptide angiotension 1 subtype; angiotension 2 receptor antagonist. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081309 |
SnomedCT | 108585000, 386877005 |
LNC | LP171611-9 |
English | 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one, 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, irbesartan, irbesartan (medication), IRBESARTAN, irbesartan [Chemical/Ingredient], Irbesartan, Irbesartan (product), Irbesartan (substance) |
Spanish | irbesartano (sustancia), irbesartano, irbesartán (producto), irbesartán (sustancia), irbesartán |
Ontology: Cozaar (C0591301)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D019808 |
English | cozaar, Cozaar |
Ontology: Avapro (C0595301)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081309 |
English | irbesartan (Avapro), avapro, aprovel, karvea, Aprovel, Karvea, Sanofi Winthrop Brand of Irbesartan, BMS Brand of Irbesartan, Bristol Myers Brand of Irbesartan, Avapro |
Ontology: candesartan (C0717550)
Definition (NCI) | A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081643 |
SnomedCT | 108587008, 372512008 |
LNC | LP171390-0 |
English | 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole, 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid, candesartan [Chemical/Ingredient], CANDESARTAN, candesartan, Candesartan (product), Candesartan (substance), Candesartan |
Spanish | candesartano (sustancia), candesartano, candesartán (producto), candesartán (sustancia), candesartán |
Ontology: Atacand (C0718711)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C077793 |
English | Atacand, atacand, blopress, Amias, Blopress, Astra brand of candesartan cilexetil, AstraZeneca brand of candesartan cilexetil, Kenzen, Promed brand of candesartan cilexetil, Takeda brand of candesartan cilexetil |
Ontology: Diovan (C0719949)
Definition (CHV) | brand name of a high blood pressure medication |
Definition (CHV) | brand name of a high blood pressure medication |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C081489 |
English | Diovan, valsartan (Diovan), diovan, diovan [brand name], Novartis brand of valsartan, Tareg |
Ontology: Micardis (C0721704)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C084178 |
English | Micardis, telmisartan (Micardis), micardis, Boehringer Ingelheim brand of telmisartan, Abbott brand of telmisartan |
Ontology: Teveten (C0876891)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C068373 |
English | Teveten, teveten |
Ontology: olmesartan (C1098320)
Definition (NCI) | A synthetic imidazole derivative and angiotensin II receptor antagonist with antihypertensive activity. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor subtype in vascular smooth muscle and adrenal gland, thereby competing with angiotensin II for binding to the AT1 receptor. This prevents angiotensin II-induced vasoconstriction and interferes with angiotensin II-mediated aldosterone secretion, thereby decreasing aldosterone production and preventing aldosterone-stimulated sodium retention and potassium excretion. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C437965 |
SnomedCT | 385540001, 412259001 |
English | olmesartan [Chemical/Ingredient], omesartan, OLMESARTAN, Olmesartan (product), Olmesartan, Olmesartan (substance), olmesartan, 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid |
Spanish | olmesartán (producto), olmesartán, olmesartán (sustancia) |
Ontology: Benicar (C1122245)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C097933 |
English | benicar, Forest Brand of Olmesartan Medoxomil, Olmetec, Sankyo Brand of Olmesartan Medoxomil, Benicar |